Navigation Links
Diuretics Best for Hypertension and Metabolic Syndrome
Date:1/28/2008

Drugs as good or better than others in treating both conditions

MONDAY, Jan. 28 (HealthDay News) -- Diuretics appear to be as good or better than other blood pressure drugs for treating hypertension in patients with metabolic syndrome, especially black patients, according to a U.S. study.

People with hypertension and metabolic syndrome are at high risk for complications of cardiovascular disease.

Researchers at Case Western Reserve University and University Hospitals Cases Medical Center in Cleveland analyzed data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

It included 42,418 people with hypertension and at least one other risk factor for cardiovascular disease who were randomly assigned to take either the diuretic chlorthalidone (15,255), the calcium channel blocker amlodipine besylate (9,048), the alpha-blocker doxazosin mesylate (9,061), or the ACE inhibitor lisinopril (9,054).

Each drug was used to start treatment, and other drugs were added if necessary to control blood pressure. The majority of patients were followed for an average of 4.9 years, but the alpha-blocker part of the trial was halted after an average of 3.2 years due to increased rates of cardiovascular disease.

Among the patients in the study, 23,077 met the criteria for metabolic syndrome, which is defined as hypertension plus at least two of the following factors: diabetes or pre-diabetes; a body-mass index (BMI) of at least 30; high triglyceride levels; or low levels of high-density lipoprotein ("good" cholesterol).

"No differences were noted among the four treatment groups, regardless of race or metabolic syndrome status for the primary end point (nonfatal myocardial infarction [heart attack] and fatal coronary heart disease)," the study authors wrote.

Among patients with metabolic syndrome, those taking the diuretic had a lower rate of heart failure than those taking the other three drugs. Patients who took the ACE inhibitor and the alpha-blocker also had an increased risk of combined cardiovascular disease.

"The lack of benefit of the agents with the most favorable metabolic profile [i.e., ACE inhibitors and alpha-blockers] was especially marked in black participants with metabolic syndrome," the researchers wrote.

"The magnitude of excess risk of end-stage renal [kidney] disease [70 percent], heart failure [49 percent] and stroke [37 percent] and the increased risk of combined cardiovascular disease and combined coronary heart disease strongly argue against the preference of ACE inhibitors over diuretics as the initial therapy in black patients with metabolic syndrome. Similar high risk was noted for those randomized to the alpha-blocker versus the diuretic."

The researchers concluded that the findings "fail to provide support for the selection of alpha-blockers, ACE inhibitors, or calcium channel blockers over thiazide-type diuretics to prevent cardiovascular or renal outcomes in patients with metabolic syndrome, despite their more favorable metabolic profiles."

The study, which received support from Pfizer Inc., was published in the Jan. 28 issue of the Archives of Internal Medicine.

More information

The American Academy of Family Physicians has more about metabolic syndrome.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, Jan. 28, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in San Antonio
2. Hispanics hypertension better controlled with equal access to care
3. Hypertension Diagnostics Announces Fiscal Year 2007 Results
4. Weight Loss Can Control Hypertension
5. Combination therapy reverses effects of portal hypertension in rats
6. Hypertension Triples Womens Diabetes Risk
7. Study links hypertension in obese children to television viewing
8. Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
9. Mexicos expanded health insurance improves hypertension treatment
10. Spirituality Helps Older Black Women Beat Hypertension
11. A new method allows for the early diagnosis of pulmonary hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Diuretics Best for Hypertension and Metabolic Syndrome
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
(Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery ... Arizona pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic ... , Dr. Olson says the decision to support the pageant in an ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based ... however, are unsure how to move forward, given the need to sustain current ... forward tailored to an organization’s specific needs. , PYA Principal Martie Ross states, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: